KNSA - CIK 0001730430
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported revenue of $677.56M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $677.56M | +60.1% |
| FY 2024 | $423.24M | +56.6% |
| FY 2023 | $270.26M | +22.7% |
| FY 2022 | $220.18M | +471.2% |
| FY 2021 | $38.54M | - |
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported revenue of $677.56M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2021 and fiscal 2025, Kiniksa Pharmaceuticals, Ltd.'s revenue grew from $38.54M to $677.56M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.